3D Bioprinted Human Tissue Market Report 2025

The 3D bioprinted human tissue market size has grown rapidly in recent years. It will grow from $1.7 billion in 2024 to $1.93 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to the rising demand for organ transplantation, the increasing prevalence of chronic diseases, greater investment in regenerative medicine, the expansion of stem cell research, and the growing adoption of personalized medicine.

The 3D bioprinted human tissue market size is expected to see rapid growth in the next few years. It will grow to $3.18 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to the rising demand for organ transplantation, the increasing prevalence of chronic diseases, greater investment in regenerative medicine, the continued expansion of stem cell research, and the growing use of personalized medicine. Key trends anticipated during this period include advancements in bio-ink technologies, innovations in tissue engineering, rapid progress in stem cell bioprinting, expanding research and development activities, and the emergence of multi-material and multi-cell printing systems.

The rising demand for organ transplants is expected to drive the growth of the 3D bioprinted human tissue market in the coming years. Organ transplantation is a medical procedure in which organs are transferred from a donor to a recipient to replace damaged or failing organs. The growing demand for these procedures stems from patients seeking life-saving treatments that reduce waiting times, improve survival rates, and provide reliable transplant solutions. 3D bioprinted human tissue offers a breakthrough alternative by enabling the creation of patient-specific, functional tissues that lower the risk of rejection and reduce reliance on donor organs. For instance, in January 2024, the Organ Procurement and Transplantation Network, a US-based Department of Health and Human Services entity, reported that organ transplants from living and deceased donors totaled 46,632 in 2023, an 8.7% increase over 2022 and a 12.7% increase over 2021 marking the first time more than 40,000 organ transplants were performed in a single year. Therefore, the increasing demand for organ transplants is fueling growth in the 3D bioprinted human tissue market.

Companies in the 3D bioprinted human tissue market are advancing technological innovations such as patient-derived sample optimization to enhance the accuracy and personalization of tissue models for drug discovery, disease research, and regenerative medicine. Patient-derived sample optimization refers to the efficient use of limited patient cells to generate multiple high-quality, biologically relevant 3D tissue models for more precise research outcomes. For example, in January 2025, Inventia Life Science Pty Ltd., an Australia-based biotechnology firm, introduced the RASTRUM solution within its product suite to enable the rapid, reproducible, and precise creation of complex 3D human tissue models. These models closely mimic real human tissues for use in drug testing, disease modeling, and regenerative medicine. Using advanced drop-on-demand bioprinting technology, the platform automates and scales the production of 3D cell cultures in standard lab plate formats, reducing manual work and variability. This advancement supports high-throughput experiments with consistent and biologically relevant results, accelerating discoveries and improving preclinical research predictability.

In May 2022, BICO Group AB, a Sweden-based provider of life science and bioconvergence technologies, acquired Allegro 3D Inc. for an undisclosed amount. This acquisition was aimed at expanding BICO’s bioprinting portfolio by incorporating Allegro 3D’s advanced light-based photolithography technology to accelerate the development of innovative products in tissue engineering and regenerative medicine. Allegro 3D Inc. is a US-based manufacturer of 3D bioprinted human tissues.

Major players in the 3d bioprinted human tissue market are 3D Systems Corporation, Inventia Life Science PTY LTD., Aspect Biosystems Ltd., Cellink Global AB, Prellis Biologics Inc., Cyfuse Biomedical K.K., Poietis SAS, Fluidform LLC, Tissuelabs, Brinter Oy, EpiBone Inc., Carcinotech Ltd., VoxCell BioInnovation Inc., Organovo Holdings Inc., Biolife 4D, Vivax-bio, CollPlant Biotechnologies Ltd., Xolo, Copner Biotech, and TissueTinker.

North America was the largest region in the 3D bioprinted human tissue market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in 3D bioprinted human tissue market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the 3D bioprinted human tissue market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

3D bioprinted human tissue refers to three-dimensional structures produced using bioprinting technology, which deposits living cells, bioinks, and biomaterials layer by layer to fabricate tissue. The primary goal of 3D bioprinted tissues is to create functional models for applications such as regenerative medicine, drug testing, disease modeling, and, in the future, organ transplantation.

The primary types of 3D bioprinted human tissue include skin, cartilage, liver, bone, heart, and others. Skin tissue refers to bioprinted layers designed to mimic the body’s protective outer covering, with applications in wound healing and grafting. Various bioprinting technologies are used, including extrusion-based systems, inkjet bioprinting, laser-assisted bioprinting, microfluidic and acoustic methods, magnetic levitation, and hybrid or 4D approaches. A wide range of materials can be employed, such as natural biomaterials, synthetic biomaterials, decellularized extracellular matrices, hydrogels, composite materials, and others. These tissues are applied in fields such as tissue engineering, cosmetic surgery, drug testing and development, and food testing, and are utilized by end users including pharmaceutical companies, biotechnology firms, academic and research institutions, contract research organizations, and hospitals and clinics.

The 3D bioprinted human tissue market research report is one of a series of new reports that provides 3D bioprinted human tissue market statistics, including 3D bioprinted human tissue industry global market size, regional shares, competitors with a 3D bioprinted human tissue market share, detailed 3D bioprinted human tissue market segments, market trends and opportunities, and any further data you may need to thrive in the 3D bioprinted human tissue industry. This 3D bioprinted human tissue market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The 3D bioprinted human tissue market consists of revenues earned by entities by providing services such as commercial manufacturing of bioprinted tissues, drug testing and development, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The 3D bioprinted human tissue market also includes sales of bioinks, tissue constructs for transplantation, synthetic and natural polymers, hydrogels, and scaffold materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.